Table 2. Characteristics of the cohort of patients with CRC used to characterise phenotype of MDDCs (A) and the characteristics of patients with CRC used to investigate the effect of TCM on autologous MDDCs (B).
| Stage I | Stage II | Stage III | Stage IV | |
|---|---|---|---|---|
|
(A) MDDCs obtained from patients with colorectal cancer (n=31) | ||||
| N | 6 | 15 | 9 | 1 |
| Male/Female | 4/2 | 9/6 | 3/6 | Male |
| Lymphovasular invasion | 0 | 5 | 5 | 1 |
| Perineural infiltration | 0 | 1 | 3 | 1 |
| Mismatch repair loss | 0 | 1 | 2 | 0 |
| KRAS mutation | Not tested | Not tested | 0 | 1 |
| Tumour budding |
1 |
0 |
3 |
3 |
|
(B) Autologous TCM and MDDCs obtained from patients with colorectal cancer (n=13) | ||||
| N | 1 | 11 | 1 | |
| Male/Female | Male | 8/3 | Female | |
| Age (median, range) | 63 | 68.5 (50–84) | 51 | |
| Lymphovascular invasion | 0 | 1 | 1 | |
| Perineural infiltration | 0 | 1 | 0 | |
| Mismatch repair loss | 0 | 1 | 0 | |
| KRAS mutation | Not tested | Not tested | 0 | |
| Tumour budding | 1 | 1 | 0 | |
Abbreviations: CRC=colorectal cancer; MDDC=monocyte-derived dendritic cell; TCM=tumour-conditioned media.